Table I.
Correlations between PAK5 expression and clinicopathological factors of patients with gastric cancer.
| PAK5 expression | ||||
|---|---|---|---|---|
| Clinicopathological factors | Patients, n | Low (n=235) | High (n=44) | P-value |
| Age | ||||
| ≥70 years | 110 | 92 | 18 | 0.826 |
| <70 years | 169 | 143 | 26 | |
| Sex | ||||
| Male | 213 | 174 | 39 | 0.037 |
| Female | 66 | 61 | 5 | |
| Location | ||||
| L, M | 224 | 192 | 32 | 0.170 |
| U | 55 | 43 | 12 | |
| Pathological type | ||||
| Differentiated | 129 | 97 | 32 | <0.001 |
| Undifferentiated | 150 | 138 | 12 | |
| Depth of invasion | ||||
| T1 | 116 | 110 | 6 | <0.001 |
| T2/T3/T4 | 163 | 125 | 38 | |
| Lymph node metastasis | ||||
| N0 | 144 | 132 | 12 | <0.001 |
| N1/N2/N3 | 135 | 103 | 32 | |
| Distant metastasis or recurrence | ||||
| Negative | 195 | 170 | 25 | 0.038 |
| Positive | 84 | 65 | 19 | |
| Stage | ||||
| I | 133 | 122 | 11 | 0.001 |
| II/III/IV | 146 | 113 | 33 | |
PAK5, P21-activated kinase 5. L, lower third of the stomach; M, middle third of the stomach; U, upper third of the stomach.